EP0981642A4 - Kinase inhibitrice de nf-kappa b kappa b, sous-unites de la kinase kappa b et procedes d'utilisation - Google Patents

Kinase inhibitrice de nf-kappa b kappa b, sous-unites de la kinase kappa b et procedes d'utilisation

Info

Publication number
EP0981642A4
EP0981642A4 EP98908673A EP98908673A EP0981642A4 EP 0981642 A4 EP0981642 A4 EP 0981642A4 EP 98908673 A EP98908673 A EP 98908673A EP 98908673 A EP98908673 A EP 98908673A EP 0981642 A4 EP0981642 A4 EP 0981642A4
Authority
EP
European Patent Office
Prior art keywords
kappa
kinase
methods
inhibitor
subunits
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP98908673A
Other languages
German (de)
English (en)
Other versions
EP0981642A1 (fr
Inventor
Michael Karin
Joseph A Didonato
David M Rothwarf
Makio Hayakawa
Ebrahim Zandi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California Berkeley
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/810,131 external-priority patent/US6268194B1/en
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Publication of EP0981642A1 publication Critical patent/EP0981642A1/fr
Publication of EP0981642A4 publication Critical patent/EP0981642A4/fr
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/1101—IkappaB kinase (2.7.11.10)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
EP98908673A 1997-02-25 1998-02-23 Kinase inhibitrice de nf-kappa b kappa b, sous-unites de la kinase kappa b et procedes d'utilisation Ceased EP0981642A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US810131 1997-02-25
US08/810,131 US6268194B1 (en) 1997-02-25 1997-02-25 IKB kinase and methods of using same
US6147097P 1997-10-09 1997-10-09
US61470P 1997-10-09
PCT/US1998/003511 WO1998037228A1 (fr) 1997-02-25 1998-02-23 KINASE INHIBITRICE DE NF-λB (IλB), SOUS-UNITES DE LA KINASE IλB ET PROCEDES D'UTILISATION

Publications (2)

Publication Number Publication Date
EP0981642A1 EP0981642A1 (fr) 2000-03-01
EP0981642A4 true EP0981642A4 (fr) 2003-03-19

Family

ID=26741107

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98908673A Ceased EP0981642A4 (fr) 1997-02-25 1998-02-23 Kinase inhibitrice de nf-kappa b kappa b, sous-unites de la kinase kappa b et procedes d'utilisation

Country Status (5)

Country Link
EP (1) EP0981642A4 (fr)
JP (2) JP4125379B2 (fr)
AU (1) AU740622B2 (fr)
CA (1) CA2281955C (fr)
WO (1) WO1998037228A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000510328A (ja) 1996-03-19 2000-08-15 プロスクリプト・インコーポレイテッド ＩкＢαを部位特異的にリン酸化し得るキナーゼ
US6235512B1 (en) * 1997-07-01 2001-05-22 Tularik Inc. IKK-α proteins, nucleic acids and methods
US5851812A (en) * 1997-07-01 1998-12-22 Tularik Inc. IKK-β proteins, nucleic acids and methods
US6087169A (en) 1997-08-04 2000-07-11 Smithkline Beecham Plc HKABY60: polynucleotide encoding a helix-loop-helix ubiquitous kinase family polypeptide
EP0897009A3 (fr) * 1997-08-04 1999-06-09 Smithkline Beecham Plc HKABY60 polypeptides
US6030834A (en) * 1997-12-30 2000-02-29 Chiron Corporation Human IKK-beta DNA constructs and cells
JP2003526608A (ja) * 1998-10-15 2003-09-09 バイオイメージ エイ／エス 再分布及び／又は標的化での干渉によって得られる特異的治療の介入
US5977341A (en) * 1998-11-20 1999-11-02 Isis Pharmaceuticals Inc. Antisense modulation of inhibitor-kappa B kinase-beta expression
US5962673A (en) * 1998-11-20 1999-10-05 Isis Pharmaceuticals Inc. Antisense modulation of inhibitor-kappa B kinase-alpha expression
FR2787119A1 (fr) * 1998-12-09 2000-06-16 Inst Nat Sante Rech Med Procede de criblage en levure d'inhibiteurs de proteines kinases specifiques de cellules humaines et de mammiferes
US6468755B1 (en) 1999-08-10 2002-10-22 Joslin Diabetes Center, Inc. Method for identifying compounds for treatment of insulin resistance
US6630312B2 (en) 1999-08-10 2003-10-07 Joslin Diabetes Center, Inc. Method for identifying compounds for treatment of insulin resistance
US6642215B2 (en) * 2001-05-24 2003-11-04 Leo Pharma A/S Method of modulating NF-kB activity
KR101889140B1 (ko) * 2015-10-12 2018-08-17 연세대학교 산학협력단 p65의 전사 조절 도메인과 단백질 운반 도메인을 포함하는 신규 융합 단백질 및 이의 용도
CN115819603A (zh) * 2022-12-26 2023-03-21 广西大学 一种猪IKKα多克隆抗体的制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998008955A1 (fr) * 1996-08-26 1998-03-05 Signal Pharmaceuticals, Inc. Agent caracterise par un signal i(kappa)b kinase [ikk] inductible par stimulus
WO1999001542A1 (fr) * 1997-07-01 1999-01-14 Tularik Inc. PROTEINES IKK-β, ACIDES NUCLEIQUES ET PROCEDES
EP0897009A2 (fr) * 1997-08-04 1999-02-17 Smithkline Beecham Plc HKABY60 polypeptides

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998008955A1 (fr) * 1996-08-26 1998-03-05 Signal Pharmaceuticals, Inc. Agent caracterise par un signal i(kappa)b kinase [ikk] inductible par stimulus
WO1999001542A1 (fr) * 1997-07-01 1999-01-14 Tularik Inc. PROTEINES IKK-β, ACIDES NUCLEIQUES ET PROCEDES
EP0897009A2 (fr) * 1997-08-04 1999-02-17 Smithkline Beecham Plc HKABY60 polypeptides

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHEN Z J ET AL: "SITE-SPECIFIC PHOSPHORYLATION OF IKAPPABALPHA BY A NOVEL UBIQUITINATION-DEPENDENT PROTEIN KINASE ACTIVITY", CELL, CELL PRESS, CAMBRIDGE, NA, US, vol. 84, 22 March 1996 (1996-03-22), pages 853 - 862, XP002037788, ISSN: 0092-8674 *
CONNELLY M A ET AL: "CHUK, A NEW MEMBER OF THE HELIX-LOOP-HELIX AND LEUCINE ZIPPER FAMILIES OF INTERACTING PROTEINS, CONTAINS A SERINE-THREONINE KINASE CATALYTIC DOMAIN", CELLULAR AND MOLECULAR BIOLOGY RESEARCH, vol. 41, no. 6, 1995, pages 537 - 549, XP002914743 *
REGNIER C H ET AL: "IDENTIFICATION AND CHARACTERIZATION OF AN IKAPPAB KINASE", CELL, CELL PRESS, CAMBRIDGE, NA, US, vol. 90, no. 2, 25 July 1997 (1997-07-25), pages 373 - 383, XP002053258, ISSN: 0092-8674 *
See also references of WO9837228A1 *

Also Published As

Publication number Publication date
CA2281955C (fr) 2009-09-08
AU6664698A (en) 1998-09-09
EP0981642A1 (fr) 2000-03-01
JP2008115164A (ja) 2008-05-22
AU740622B2 (en) 2001-11-08
WO1998037228A1 (fr) 1998-08-27
JP2001524813A (ja) 2001-12-04
CA2281955A1 (fr) 1998-08-27
JP4125379B2 (ja) 2008-07-30

Similar Documents

Publication Publication Date Title
ID18142A (id) Inhibitor metaloprotease 1,4-heterosiklik
ID18141A (id) Inhibitor metaloprotease 1,3-diheterosiklik
ID17275A (id) N-[4-(heteroarilmetil)fenil]-heteroarilamina
NO982732D0 (no) Ny fremgangsmÕte
FI963597A7 (fi) Isoprenyylitransferaasi-inhibiittoreita
NO972930D0 (no) Fibronectin-adhesjonsinhibitorer
PT936906E (pt) Inibidores do refluxo
FI972160A0 (fi) Matriisimetalloproteaasi-inhibiittorit
ID17874A (id) Alat penyaluran
NO973216L (no) Substituerte oksazolidin-calpain- og/eller cathepsin B-inhibitorer
NO994906L (no) GnRH antagonister som er modifisert i stillinger 5 og 6
DK1027332T3 (da) Hidtil ukendte lactametalloproteaseinhibitorer
DE69716615D1 (de) Heterozyklische metalloproteaseinhibitoren
DK0958287T3 (da) Sulfamidmetalloprotease-inhibitorer
EP0981642A4 (fr) Kinase inhibitrice de nf-kappa b kappa b, sous-unites de la kinase kappa b et procedes d'utilisation
EP1012266A4 (fr) Galectine 8, 9, 10, et 10sv
PT927183E (pt) Inibidores espirociclicos de metaloproteases
DE69601423D1 (de) Federball
PT948483E (pt) Inibidores da farnesil-transferase
NO993298L (no) Ny fremgangsmÕte
NO995796D0 (no) Ny fremgangsmåte
DE69733263D1 (de) Markierte elastase-inhibitoren
PT811593E (pt) Agentes insecticidas e acaricidas 1,4-diaril-2-fluor-2-buteno
BR9610514A (pt) Inibidores cicloantihelmínticos
EP1007548A4 (fr) Inhibiteur de thrombine provenant de la mouche tse-tse

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990921

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIN1 Information on inventor provided before grant (corrected)

Inventor name: ZANDI, EBRAHIM, USC NORRIS COMP.CANCER CENTER

Inventor name: HAYAKAWA, MAKIO

Inventor name: ROTHWARF, DAVID, M.

Inventor name: DIDONATO, JOSEPH, A.

Inventor name: KARIN, MICHAEL

A4 Supplementary search report drawn up and despatched

Effective date: 20030131

17Q First examination report despatched

Effective date: 20031219

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20080208